Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for pneumonia

Abstract A prospective study was performed to determine serotype distribution and antimicrobial resistance in Streptococcus pneumoniae ( S. pneumoniae ) from Chinese children <5 years old meeting pneumonia criteria. A total of 3865 children were enrolled and 338 S. pneumoniae isolates were obtain...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 29; no. 12; pp. 2296 - 2301
Main Authors: Yao, Kai-Hu, Wang, Li-Bo, Zhao, Gen-Ming, Zheng, Yue-Jie, Deng, Li, Huang, Jing-Fu, Wang, Jie-Xiu, Zhao, Rui-Zhen, Deng, Qiu-Lian, Hu, Ying-Hui, Yu, Sang-Jie, Yang, Yong-Hong, Young, Mariano
Format: Journal Article
Language:English
Published: Kidlington Elsevier Ltd 09-03-2011
Elsevier
Elsevier Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A prospective study was performed to determine serotype distribution and antimicrobial resistance in Streptococcus pneumoniae ( S. pneumoniae ) from Chinese children <5 years old meeting pneumonia criteria. A total of 3865 children were enrolled and 338 S. pneumoniae isolates were obtained. The most frequent serotypes were 19F (55.6%), 19A (13.9%), 23F (10.1%), 6B (4.7%), and 14 (3.6%). The 7-, 10- and 13-valent conjugate vaccines, respectively, covered 76.3%, 76.9%, and 92.3% of isolates. Out of the isolates, six (1.8%) were penicillin resistant. All except 1 of the isolates were resistant to erythromycin. Serotype 19A showed the highest drug resistance. The use of PCV7 has the potential to prevent a substantial number of pneumococcal infections. However, PCV13 is likely to prevent more episodes of pneumococcal disease in China because of the high rates of 19A.
Bibliography:http://dx.doi.org/10.1016/j.vaccine.2011.01.027
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.01.027